Clinical Effects of Soy Isoflavone Aglycones on Menopausal Symptoms


Bibliographic Information

Other Title
  • 大豆イソフラボンアグリコンの更年期障害に対する効果について

Search this article


The purpose of this study was to evaluate the clinical effects of Soy Isoflavone Aglycones (IFA) on menopausal symptoms. IFA were administered to fourteen postmenopausal women aged 48-56 years at a dose of 40mg/day for three months periods. The scores of menopausal symptoms were monitered using check-sheets by Tokyo Medical and Dental University, before IFA intake, and after one, two and three months. Serum IFA level, estradiol E2, FSH and other biochemical factors were measured at the same time. Three months after first trial (wash-out period), the same women were administered tablets without IFA, and studied the same way as placebo groups. The scores of menopausal symptoms in IFA groups were significantly decreased from 30.82±12.92 to 23.46±10.55 and 20.64±9.9, respectively, after two and three months as compared with placebo groups (p< 0.01). The severity and frequency of hot flashes were also reduced from 6.36±3.14 to 2.73±2.49 and 2.18± 1.4 by the score (p < 0.01). Associating with these improving menopausal symptoms, serum IFA levels were increased from baseline level by 1.62±0.75, μ mol/L,1.64±0.7, μ mol/L and 1.49±1.37, μ mol/L after one, two and three months, respectively (p < 0.01). There was no difference in serum estradiol, FSH and other biochemical factors. These results demonstrated beneficial effects of IFA on improving menopausal symptoms.


Details 詳細情報について

Report a problem

Back to top